^
    Back
    Association details:
    Biomarker:Chr amplification(1q)
    Cancer:Multiple Myeloma
    Regimen:Isa-KRd (carfilzomib + dexamethasone injection + lenalidomide + Sarclisa (isatuximab-irfc))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    3239 A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)Clinically Relevant Abstract

    Published date:
    11/03/2022
    Excerpt:
    For maintenance, patients were stratified based on cytogenetics (high-risk cytogenetics included deletion 17p, gain of 1q, and translocations t(4:14), t(14;16), t(14;20))….Of the 47 patients evaluable for response after 4 cycles, the ORR was 100% and 89% (42/47) achieved a very good partial response (VGPR) or better and 40% (19/47) a CR....Early data suggest that Isa-KRd induces deep responses in patients with NDMM.
    DOI:
    https://doi.org/10.1182/blood-2022-156328
    Trial ID:
    SKylaRk